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Background: Most patients with primary antibody deficiency (PAD) suffer from less
well-described and understood forms of hypogammaglobulinemia (unclassified primary
antibody deficiency, unPAD). Because of the moderately decreased immunoglobulin
levels compared to CVID, unPAD is generally considered to be clinically mild and not
very relevant.
Objective: To describe our cohort of—mainly—unPAD patients, and to analyze whether
subgroups can be identified.
Methods: Data were prospectively collected (February-2012 to June-2016) as part
of a standardized, 1-day Care Pathway for suspected primary immunodeficiency. The
TNO-AZL Questionnaire for Health-Related Quality of Life (HRQoL) was part of the
pre-first-visit intake procedure.
Results: Three hundred and twenty patients were referred to the Care Pathway. Data
from 23/27 children and 99/113 adults who were diagnosed with PAD and gave informed
consent were available for analysis. 89/99 adults had unPAD, the majority (74%) were
female and 44% already showed bronchiectasis. HRQoL was significantly decreased
in all domains, meaning that a lot of unPAD patients had to cope simultaneously with
pain, negative feelings and impairments in cognition, home management tasks, sleep,
social interaction, and work. The most prominently impaired HRQoL domain was vitality,
indicating these patients feel extremely tired and worn out.
Conclusion: These results highlight the need for more attention to the potential patient
burden of unPADs. A larger cohort is needed to increase our understanding of unPADs
and to analyze whether distinct subgroups can be identified. For now, it is important
for the clinician to acknowledge the existence of unPAD and be aware of its potential
consequences, in order to timely and appropriately manage its effects and complications.
Keywords: primary antibody deficiency, immunodeficiency, unclassified primary antibody deficiency, primary
immunodeficiency, hypogammaglobulinemia, common variable immunodeficiency disorders, pneumococcal
vaccination response
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INTRODUCTION
Primary immune deficiencies (PIDs) are rare, inherited defects
of the immune system with more than 300 forms described to
date (1). Only a small subgroup of patients suffer from a form of
PID that leads to significant problems very early in life (2). Most
PID patients have PID forms that are less severe and present later
in life (1–4), mainly comprising of diseases with predominantly
(primary) antibody deficiency (PAD). PADs can be divided into
agammaglobulinemias, defects of class switch recombination,
and hypogammaglobulinemias. Hypogammaglobulinemia is by
far the most common entity, comprising nearly half of all
PID diagnoses (2, 4). In specialized centers, common variable
immunodeficiency disorder (CVID) is the most common form
of hypogammaglobulinemia seen (estimated prevalence in the
population 1:10,000–50,000) (5, 6). In the ESID Registry, CVID
is strictly defined: age >4 years, markedly decreased serum IgG
and IgA with or without low IgM, poor antibody response to
vaccines, and exclusion of an underlying cause (http://www.
esid.org). Many more patients live with less well described
and understood forms of hypogammaglobulinemia: deficiency
of IgG, IgG-subclass(es), IgM, IgA, and/or specific antibodies,
alone, or in combination(s) (4). We refer to these forms as
unclassified primary antibody deficiency (unPAD). Because of
the moderately decreased immunoglobulin levels, unPADs are
generally considered to be clinically milder. However, data
regarding the clinical presentation, prognosis and treatment of
unPAD patients are limited. These patients generally do not
visit physicians in specialized/tertiary centers, and are often not
treated with the immunodeficiency taken into consideration.
The symptoms of patients with hypogammaglobulinemia can
lead to decreased quality of life, increased loss of participation
in society (school, work) and higher health care costs (7–12).
These patients often go unrecognized, because the general public
as well as most health care professionals, who are not specialized
in immunodeficiency, do not consider potential PID in patients
with recurrent “normal” infections (responding to regular
treatment, and not caused by an unexpected or opportunistic
pathogen). Their concomitant fatigue is often interpreted to be
of psychosocial origin or labeled as chronic fatigue syndrome.
To improve awareness and early detection of PID in patients
with recurrent normal infections, we developed a Care Pathway
for suspected primary immunodeficiency in the Jeroen Bosch
hospital (JBZ), a large teaching hospital (secondary center) in
the southern part of the Netherlands. All patient data obtained
in regular care in the Pathway were collected and stored
Abbreviations: BMI, body mass index; CVID, common variable
immunodeficiency disorders; ENT, ear nose throat; ESID, European Society for
Immunodeficiencies; HRCT, high resolution computerized tomography; HRQoL,
health-related quality of life; IgGsc, IgG-subclass; IQR, inter-quartile range; JBZ,
Jeroen Bosch hospital; yrs, years; LISS, Longitudinal Internet Studies for the
Social sciences; PAD, predominantly (primary) antibody deficiency; PID, primary
immunodeficiency; PP, pneumococcal polysaccharide; PVR, pneumococcal
vaccination response; SD, standard deviation; TAAQOL, TNO-AZL questionnaire
for adult’s HRQoL (≥16 years of age); TACQOL, TNO-AZL questionnaire for
children’s HRQoL (6–15 years of age); TAPQOL, TNO-AZL questionnaire for
pre-school children’s HRQoL (1–5 years of age); unPAD, unclassified primary
antibody deficiency.
electronically. In this report, we present a detailed analysis of
the available clinical data from the patients diagnosed with PAD
during the first 4 years of the Pathway who gave informed consent
for using their data for this purpose; these were mostly unPAD
patients.
MATERIALS AND METHODS
Study Design
Data were prospectively collected, pseudonymized, and stored on
a protected server using Research Manager software developed
by Cloud9 Health Solutions (Deventer, the Netherlands) as part
of a standardized, 1-day Care Pathway for suspected PID. Data
were collected on all patients referred to the Care Pathway
from the start in February 2012 to June 2016. The primary
objective of this study was to describe the patients, with special
focus on unPAD patients, for this project including “deficiency
of specific IgG (specific antibody deficiency—SPAD),” “IgA
with IgG subclass deficiency,” “isolated IgG subclass deficiency,”
“selective IgM deficiency,” and “selective IgA deficiency.” The
secondary objective was to analyze whether subgroups could be
identified. Only participants who gave written informed consent
were included in this study; the Medical Ethical Committee
Brabant approved the study.
The Care Pathway
Patients were referred to the Care Pathway when there was
a suspicion of potential immunodeficiency. Upon referral,
data were collected electronically on patient and family
history, and previous medical information was requested. Based
on this information, the immunologist (author De Vries)
decided whether visiting the Care Pathway was indicated,
based on the clinical presentations of PID as presented
in the ESID diagnostic protocol (3, 13). Patients could be
referred by general practitioners or by medical specialists
(e.g., pulmonologists, internists, ENT-surgeons, dermatologists).
Seventy-seven percent lived in the encashment area of the JBZ
(320,000 people), the remaining patients were referred from
other parts of the country.
The Care Pathway comprised a visit to an immunologist
specialized in the field of PID (author De Vries), in addition to
indicated laboratory and radiologic evaluations, and pulmonary
function tests. After completion of the Care Pathway, each
patient was evaluated in a multidisciplinary team, attended by
the immunologist, a pulmonologist, an internist, and specialized
nurse. The team formulated an advice for each individual
patient on: (1) presence or absence of PID, (2) indication for
treatment with immunoglobulin substitution and/or (change of)
antimicrobial prophylaxis, (3) indication for investigation of
family members, and (4) necessity of referral to a tertiary center.
Assessments
All assessments were performed during regular, routine patient
care and included online questionnaires to be completed by
patients, laboratory tests, pulmonary function tests, and imaging.
All patients recorded the following social, demographic, and
clinical characteristics: age, gender, smoking habit, previous
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symptoms, prescribed therapy, family history, and highest
education level. Health-related quality of life (HRQoL) was
measured using the age specific TNO-AZL questionnaires:
TNO-AZL Pre-school children’s Quality of Life questionnaire
(TAPQOL, parents for children aged 1–5 years), TNO-AZL
Children’s Quality of Life questionnaire (TACQOL, parents and
children for children aged 6–15 and 8–15 years, respectively),
or TNO-AZL questionnaire for adult’s HRQoL (TAAQOL, ≥16
years) (14). Items inquire about the incidence of physical,
psychological, or social problems on different domains and are
scored on a 3- or 4-point Likert scale (TAPQOL and TACQOL
“never/occasionally/often” a problem with . . . ; TAAQOL “no/a
little/some/a lot of” difficulty in . . . ). If a problem/difficulty is
reported, parents and children 8–15 years rate how the children
felt at those times on a 4-point Likert scale (TAPQOL “well/not
very well/unwell/very unwell;” TACQOL “fine/not so good/quite
bad/bad”); children 16 years and over and adult subjects rate
how much that problem bothered them on a 4-point Likert scale
(TAAQOL “not at all/a little/quite a lot/very much”). Higher
scores indicate a better HRQoL. For interpretation of the various
laboratory tests, age-matched reference values were used. For
interpretation of pneumococcal antibody responses laboratory
specific reference values were used1. Analysis of B- and T-cell
subpopulations were performed as described previously (15).The
High-resolution CT (HRCT) scans of the thorax were scored
by a thoracic radiologist according to the “Chest CT in ADS”
criteria2. Finally, the immunologist scored the diagnosis, first
clinical presentation (3, 13) and disease status of the patient.
Statistical Analysis
Continuous variables were summarized by mean and standard
deviation (SD) when normally distributed, and otherwise by
median and inter-quartile range (IQR). Categorical variables
were summarized by number and percentage. The group of
children with PAD was too small to perform statistical analyses.
The domain scores of the TAPQOL, TACQOL, and TAAQOL
were computed using the SPSS syntax provided by the authors.
To ensure similarity with the Care Pathway data, individuals
outside the observed age range of the Care Pathway patients (21–
77) were excluded from the adult reference data before analysis,
leaving data from 4,120 subjects in the reference dataset. Analyses
examining the associations between categorical variables in the
adult patients were performed using Fisher’s exact test. Analyses
examining the differences in continuous measures in the adult
patients were performed using the unpaired t-test when normally
distributed, and otherwise by the Mann-Whitney test. Because
of the great number of comparisons, only p-values < 0.01
were regarded to be statistically significant. The spearman’s rank
correlation coefficient test was used to examine the association
between IgG subclass levels and pneumococcal vaccination
response. The following cut-off values were used to describe ρ:
0.00–0.19 “very weak;” 0.20–0.39 “weak;” 0.40–0.59 “moderate;”
0.60–0.79 “strong;” and 0.80–1.0 “very strong.”
To analyze whether the adult patient group could be divided
into subgroups, K-means clustering was applied creating between
1www.umcutrecht.nl/subsite/medische-immunologie/diagnostiek
2www.chest-ct-group.eu
2 and 5 clusters. Variables that exhibited highly positively
skewed distributions were analyzed on the log scale. The
Calinski/Harabasz pseudo-F index was calculated for each cluster
solution; the solution with the largest value of this index indicated
the most distinct clustering, and was chosen as the optimal
solution. Next, the differences between clusters were examined,
by comparing variables between the clusters.
The logistic regression model was used for evaluating the
predictive effect of family history, TAAQOL domains and HRCT
findings for the patient diagnosis, classified as either CVID
(according to the ESID Registry working diagnosis criteria) (16)
or unPAD. For factors where the diagnosis was the same for
all patients in a category, it was not mathematically possible
to perform logistic regression, and Fisher’s exact test was used
instead. Firstly, the association between each factor and the
outcome was examined separately in a series of univariable
analyses. Subsequently, the joint association of the factors and
the outcome was examined in a multivariable analysis. To restrict
the number of variables in the second stage of the analysis, only
those factors with a univariable p-value of ≤ 0.10 were used for
this stage. A backwards selection procedure was used to retain
only the statistically significant variables in the final model. This
involves omitting non-significant variables, one at a time, until
only the significant variables remain.
RESULTS
The Care Pathway
From the 320 patients that were referred to the Care Pathway
between February 2012 and June 2016, 153 were shown to have
some form of PID (92% PAD). In 99 adults and 23 children with
PAD, written informed consent for inclusion in this analysis was
obtained (details of patient selection process in Figure 1).
Description of the Pediatric Patients
The group of 23 children with PAD was too small to perform
any meaningful statistical analysis. An overview of their collected
data is shown in Supplementary Table 1. The parents’ main
complaint at referral was that their child was “ill too often”
in 70%, for 83% the main reason for referral was to find out
the reason why (“what is the matter with him/her”). Fifteen
children were referred by their pediatrician, four by their general
practitioner, three by their ENT surgeon, and one by their
dermatologist. Age at referral was 2–16 yrs (mean 7.5 yrs; median
6 yrs); boys predominated (74%). The clinical presentation (3, 13)
was “recurrent ENT and airway infections” in 78%. Thirty-nine
percent had an iron deficiency and 39% had an increased total
IgE, one third of these had≥1 positive specific IgE in their serum
(tree pollen, house dust mite, cat dander, dog dander, and/or
grass pollen). In 22%, other family member(s) also had a PAD
diagnosis (already known in three, not yet known in two cases).
A pulmonary HRCT scan was performed in five patients; two
showed bronchopathy, none bronchiectasis. In 41%, a mild to
moderate decrease in HRQoL was reported. Five were put on
prophylactic co-trimoxazole, two on subcutaneous, and two on
intravenous immunoglobulin substitution.
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320 referrals to the Care Path 
107 children (<18 yrs at referral) 213 adults (≥18 yrs at referral) 
5 no show 20 no show 
63 no ID 51 no ID 
of these 12 allergy, 7 
iron deﬁciency, 1 both 
5 MBL deﬁciency 
of these 20 allergy, 
0 iron deﬁciency 
4 MBL deﬁciency 
1 secondary ID 18 secondary ID 
6 other PID 
1 cyclic neutropenia, 
1 Netherton, 
4 unclassiﬁed ID 
7 other PID 
1 ring chromosome 18, 1 probable car"lage 
hair hypoplasia, 1 CMC, 1 HIES (STAT1), 1 
hereditary angioedema, 2 unclassiﬁed ID 
27 primary an"body deﬁciency 113 primary an"body deﬁciency 
2 THI, 2 sIgMdef, 2 sIgAdef, 18 unclassiﬁed PAD, 3 CVID 
no informed consent for study inclusion: 1 sIgMdef, 3 unclassiﬁed PAD 
of these 1 HIV of these 0 HIV 
 4 sIgMdef, 4 sIgAdef, 93 unclassiﬁed PAD, 12 CVID 
no informed consent for study inclusion: 12 unclassiﬁed PAD, 2 CVID 
of these 2 allergy, 
0 iron deﬁciency 
of these 0 allergy, 
2 iron deﬁciency 
When taking all details of the ESID Registry Working Diagnoses into account, sIgA, sIgM and unclassiﬁed PAD in these pa"ents all fall under the Working Diagnosis ‘unclassiﬁed an"body deﬁciency’ (unPAD). 
23 children and 99 adults with 
PAD included for analysis 
FIGURE 1 | The population under study. Overview of all patients referred to the Care Pathway between February 2012 and June 2016 (inclusive) to answer the
question “could this be primary immunodeficiency?” When taking all details of the ESID Registry Working Diagnoses into account, sIgAdef, sIgMdef, and unclassified
PAD in these patients all fall under the Working Diagnosis “unclassified antibody deficiency” (unPAD) (16). Allergy, clinical symptoms, and proven sensitization by
specific serum IgE and/or skin prick test; CVID, common variable immunodeficiency disorders (according to the ESID Registry working diagnoses); HIV, human
immunodeficiency virus; Ig, immunoglobulin; iron deficiency, low iron stores, determined by serum ferritin level; MBL, mannose binding lectin; (other) (P)ID, (other)
(primary) immunodeficiency (other meaning other than primary antibody deficiency); sIgAdef, selective IgA deficiency (according to the ESID Registry working
diagnoses, but absence of clinical signs of T-cell deficiency was considered sufficient); sIgMdef, selective IgM deficiency (according to the ESID Registry working
diagnoses, but absence of clinical signs of T-cell deficiency was considered sufficient); THI, definite transient hypogammaglobulinemia of infancy (the antibody
deficiency has resolved during the period under study); unclassified ID resp. PAD, unclassified primary antibody resp. immuno-deficiency (according to the ESID
Registry working diagnoses); yrs, years.
FIGURE 2 | (A) The long journey patients with (un)PAD often face toward diagnosis. (B) The clinical specialists the 99 adult patients with PAD had visited prior to their
referral to the Care Pathway. The size of the nodes indicates the number of times the patients encountered that specialism and the size of the connecting lines
between two nodes indicates the number of times that patients were known to both specialisms (created by Gephi software). ENT, ear-nose-throat specialist; GP,
general practitioner; PAD, primary antibody deficiency.
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FIGURE 3 | Mean serum immunoglobulins at diagnosis of the adults with CVID vs. unPAD. CVID, common variable immunodeficiency disorder; unPAD, unclassified
primary antibody deficiency (17).
FIGURE 4 | (A) unPAD cohort (89 patients): serum immunoglobulins (g/l) at diagnosis. Each column is divided into four parts, depending on the IgG levels; those in
the light purple section with IgG ≤ 1.0 g/l; those in the dark purple section with IgG>1.0 ≤ 3.0 g/l; those in the yellow section with IgG >3.0 ≤ 6.5 g/l and those in the
orange section with IgG > 6.5 g/l. (B) For comparison: European CVID cohort (Chapel et al., 334 patients): serum immunoglobulins (g/l) at diagnosis. Unabridged
from Chapel et al. (18). Permission was obtained from the editor in chief of Blood to use the previously published (B).
Description of the Adult Patients
Of the 99 PAD patients (71 women, 72%), 89 had unPAD
(66 women, 74%), and 10 had CVID (5 women, 50%)
according to the working diagnoses used in the ESID online
Registry (16). An overview of their collected data is shown
in Supplementary Table 2. Age at referral was 21.0–77.4 yrs
(mean 51.3 yrs; median 51.5 yrs). BMI, smoking habits, and
highest educational level were comparable with the Dutch
LISS panel, a representative sample of the Dutch population
(http://www.lissdata.nl). The majority (n = 43) was referred
by their pulmonologist, followed by their general practitioner
(n = 35), and internist (n = 15). The wide variety of clinical
specialists the patients with PAD had visited prior to their
referral to the Care Pathway is illustrated in Figure 2. The main
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TABLE 1 | Absolute number of lymphocyte subpopulations in peripheral blood in
the unPAD patients.
Population N= Reference
range ×
10e9/la
Median
(IQR) × 10e9/l
Decreased
(n)
Helper T-lymphocytes
(CD3+CD4+)
75 0.5–2.0 0.9
(0.7–1.2)
4
T-lymphocytes
(CD3+)
75 0.78–3.0 1.4
(1.2–2.0)
4
Cytotoxic T-lymphocytes
(CD3+CD8+)
75 0.2–1.2 0.5
(0.3–0.7)
3
NK-cells
(CD3+CD16+and/orCD56+)
74 0.10–1.2 0.2
(0.1–0.3)
4
B-lymphocytes
(CD19+)
75 0.064–0.82 0.20
(0.11–0.30)
3
IgM only memory
B-lymphocytes
(CD19+CD27+ IgM+ IgD−)
67 0.0011–0.015 0.0034
(0.0013–0.0066)
11
Switched memory
B-lymphocytes
(CD19+CD27+ IgM− IgD−)
67 0.0045–0.13 0.021
(0.011–0.044)
6
CD21low B cells
(CD19+CD21lowCD38low)
67 0.0017–0.049 0.0058
(0.003–0.010)
7b
Naïve B-lymphocytes
(CD19+CD27− IgM+ IgD+)
67 0.028–0.55 0.09
(0.046–0.16)
10
Transitional B cells
(CD19+CD38++ IgM++)
67 0.0006–0.10 0.0082
(0.0031–0.016)
7
aFrom Schatorjé et al. (15).
b Increased CD21low cell population in 2 patients.
complaint at referral was “ill too often” in 87, with airway
infections in 35, chronic cough in 4, and ENT-infections in 9
patients. For 35 patients being extremely tired and having no
energy was their most important complaint. The immunologist
characterized the initial presentation as “recurrent ENT and
airway infections” in 88, “auto-immune or chronic inflammatory
disease; lymphoproliferation” in 10, and “unusual infections or
unusually severe course of infections” in 1 of the patients (13).
As expected by the clinical definition of CVID and unPAD,
the median immunoglobulin levels at diagnosis were lower in
patients with CVID compared to unPAD patients (Figure 3). The
high prevalence of undetectable serum IgE in the CVID patients
(57%, 4/7 patients) is in agreement with the recently published
large CVID cohort by Lawrence et al. (17), demonstrating that
low/undetectable serum IgE is characteristic of CVID. Similar to
the previously published European CVID cohort by Chapel et al.
(18), the 89 unPAD patients were divided into categories based
on presenting serum immunoglobulin levels (Figure 4). In most
unPAD patients (62%) IgG and IgA levels were between 3.1 and
6.5 and > 0.8 g/l, respectively, while in the cohort of Chapel et al.
the majority of patients (94.2%) had initial IgG levels <4.5 g/l
at diagnosis (18). Classification of the unPAD patients according
to their immunoglobulin levels and pneumococcal vaccination
response (PVR) is shown in Supplementary Figures 1, 2. Median
B and T lymphocyte counts were largely within the normal
range (Table 1). A pulmonary HRCT scan was performed in 60
patients; of these, 53 had unPAD. Of the unPAD patients, 25
(47%) showed bronchial wall thickening, 24 (44%) bronchiectasis
in one or more lobe(s), 11 (21%) central or peripheral mucus
plugging, and 10 (19%) atelectasis. Twenty patients were put on
prophylactic co-trimoxazole (CVID, n = 1; unPAD, n = 19),
6 on subcutaneous and 23 on intravenous immunoglobulin
substitution (CVID, n= 9; unPAD, n= 20).
Statistical Analyses in the Adult Patients
We assessed whether the concentrations of individual IgGsc
correlated with the response to specific vaccine challenges
(Figure 5). Spearman’s correlations between IgGsc and PVRwere
moderate for IgG2 (ρ 0.52, 95% confidence interval (CI) 0.34–
0.67, p < 0.0001), and weak for IgG4 (ρ 0.27, 95% CI 0.06–
0.47, p < 0.05). There was a weak correlation between IgG1 and
antigen-specific antibody response against tetanus toxoid (ρ 0.26,
95% CI 0.04–0.46, p< 0.05). Detailed results of all IgG subclasses
plotted on a logarithmic scale with each PP serotype are shown in
Supplementary Figures 3, 4.
The combination of PVR, IgA, and IgG at first presentation
to the Pathway could not predict bronchiectasis in the adult PAD
patients. PulmonaryHRCT scan findings were also not associated
with referring doctor type, gender, the complaint “being always
ill,” CVID vs. unPAD diagnosis, or type of prescribed therapy.
Mucus plugging occurred significantly more often in patients
with “recurrent ENT and airway infections” and/or chronic
cough (41%), compared to patients who were always tired or had
other complaints (15%) (Fisher exact test [98], p= 0.04).
Nine CVID and Eighty nine unPAD patients completed the
online TAAQOL questionnaire. Patients with unPAD scored
significantly worse (P < 0.01) on all domains compared to
the subjects in the reference dataset (Figure 6). 3/9 CVID
patients had already started immunoglobulin substitution
when completing the TAAQOL questionnaire, therefore, it is
impossible to draw conclusions from this group. In order
to create separate subgroups of similar patients, associations
between the key variables were examined. Cluster analysis
showed that specifying two clusters resulted in the highest F-
statistic (24.8). The two clusters varied significantly for all but fine
motor functioning TAAQOL domain scores, but these clusters
did not match the division between CVID and unPAD patients.
The full results of the performed analyses can be found in
Supplementary Tables 3, 4.
DISCUSSION
This description of patients with primary antibody deficiency
(PAD) is unique in its secondary center population and its focus
on unPAD. It is also the first study to examine HRQoL in
unPAD patients. Our results demonstrate that unPAD can result
in severe patient burden. Besides the high proportion of patients
suffering from bronchiectasis, their HRQoL was significantly
impaired in all domains compared to the reference population.
This study shows for the first time that many unPAD patients
had to cope simultaneously with pain, negative feelings and
impairments in cognition, home management tasks, sleep, social
interaction, and work. A small number of previous studies have
investigated HRQoL in PADs (7, 9, 19), some focusing solely on
CVID (11, 12, 20, 21), but patients with unPADwere not included
in these studies. This unPAD group, generally considered to be a
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FIGURE 5 | Correlations between vaccination responses and IgG-subclass levels. The graphs show the Spearman’s correlation coefficients and 95% confidence
interval (CI) for IgG1-4 vs. vaccination responses. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. DIP, diphtheria; TET, tetanus; PVR, pneumococcal vaccination
response.
FIGURE 6 | HR-QoL in 89 unPAD patients compared to the age-matched subjects from the reference dataset (n = 4,120). Higher scores indicate better HR-QoL
(TAAQOL); the maximum score is 100. Error bars indicate inter-quartile ratios. Statistically significant differences are indicated by an asterisk: *p < 0.01; **p < 0.001.
HR-QoL, health-related quality of life; TAAQOL, TNO-AZL questionnaire for adult’s HRQoL; unPAD, unclassified primary antibody deficiency.
“mild” form of hypogammaglobulinemia, has hardly received any
attention in the literature (22). Based on our results, we strongly
recommend to change this.
The most severely affected HRQoL domain was vitality,
indicating unPAD patients feel extremely tired and worn out.
This parallels the above-average observed frequency of fatigue
in PAD patients, not only compared to the general population,
but also compared to the total PID population (23). Fatigue is
an important and debilitating problem, because it can lead to
decreased daily activities, resulting in general deconditioning,
which further affects fatigue and HRQoL in general. Clinicians
should be aware of this.
While it was previously thought that bronchiectasis is the
result of repeated infections due to deficient antibody production
(24), there is increasing evidence that immune dysregulation
plays an important role in the disease process (25). Based on
these new insights, the high proportion of unPAD patients
suffering from bronchiectasis at presentation in our cohort
(44%)—similar to the frequency reported in the literature for
CVID patients (22, 26–29)—is not that surprising. Clearly,
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despite the only moderately decreased immunoglobulin levels
in unPAD compared to CVID patients, unPAD can result in
comparable serious pulmonary complications.
Interestingly, there were nearly twice as many boys with
unPAD in our pediatric cohort, but considerably more women
than men in the adult group (74%). This may indicate that these
diseases differ in different age groups. Perhaps unknownX-linked
disease plays a role in some of these boys with antibody deficiency
(30, 31). The female predominance in the adult unPAD patients
suggests the pathogenesis of unPAD may differ between adult
women and men. The tendency for immune dysregulation is
widely acknowledged to be greater in women (32), but it is also
possible that there are protective factors in men. It would be
interesting to confirm this pattern in a much larger cohort, and
to further explore potential gender-specific mechanisms.
IgG-subclass measurements could not predict pneumococcal
vaccination responses (PVRs), or vice versa. Only a moderate
correlation between IgG2-subclasses and PVRs was found. These
results are in agreement with previous studies in patients
with Hodgkin’s lymphoma (33), in children with chronic chest
infections (34), and in patients with IgA deficiency (35). Thus,
both are needed to fully explore the immune status of an
individual patient.
Our study has several limitations. First, the sample size was
limited. Therefore, the insignificant results of the exploration of
distinct subgroups in the unPAD cohort or differences between
the unPAD and CVID patients, might be caused by the limited
detection power. A future study in a much larger cohort
may well be able to reveal separate clinical entities; the ESID
online Registry would be a good tool for this. Second, the few
CVID patients had partly already started their immunoglobulin
substitution therapy. This means our study should be mainly
used as a thorough description of the—to date—largest cohort
of unPAD patients, not as an important source for comparison
of unPAD with CVID. Third, genetic testing was not performed
in most patients; it would be interesting to investigate this. It
is possible that mildly affected patients with a known genetic
defect are “hidden” in this cohort. Despite these limitations,
our data show, contrary to what is currently assumed by
most immunologists in specialized/tertiary centers, that “mild”
hypogammaglobulinemia can be a serious condition. Also
for those patients, early detection and adequate treatment is
important.
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